Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation

Bone Marrow Transplantation

Volumn 38, Issue 2, 2006, Pages 157-167

  Pachnio, A ^a   Dietrich, S ^a   Klapper, W ^a   Humpe, A ^a   Schwake, M ^a   Sedlacek, R ^a   Gramatzki, M ^a   Beck, C ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Allogeneic bone marrow transplantation; Graft engineering; GvHD; T cell selection

Indexed keywords

CARBOXYFLUORESCEIN; TUMOR ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW CELL; CANCER CONTROL; CELL CLONING; CELL SEPARATION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT VERSUS HOST REACTION; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DISEASE MODELS, ANIMAL; FLUORESCEINS; GRAFT VS HOST DISEASE; HOMEODOMAIN PROTEINS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; STAINING AND LABELING; SUCCINIMIDES; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 33745748030     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705411     Document Type: Article

References (44)

1. Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639-646.
2. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 1996; 14: 473-489.
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
4. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. BMJ 1956; 32: 626-627.
5. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703-712.
6. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
7. Simpson D. Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res 2000; 9: 317-325.
8. Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: Implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551-565.
9. Martin PJ, Hansen JA, Torok-Storb B, Moretti L, Press O, Storb R et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 437-444.
10. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
11. Cavazzana-Calvo M, Andre-Schmutz I, Hacein-Bey-Abina S, Bensoussan D, Le Deist F, Fischer A. Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin Hematol 2002; 39: 32-40.
12. Cavazzana-Calvo M, Fromont M, Le Deist F, Lusardi M, Coulombel L, Derocq JM et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990; 50: 1-7.
13. Fehse B, Frerk O, Goldman M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol 2000; 109: 644-651.
14. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 2002; 99: 3041-3049.
15. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002; 99: 3083-3088.
16. Cohen JL, Boyer O, Salomon B, Onclercq R, Charlotte F, Bruel S et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636-4645.
17. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
18. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
19. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198-2203.
20. van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060-1066.
21. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000; 243: 147-154.
22. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J Immunol 2001; 166: 973-981.
23. Maury S, Salomon B, Klatzmann D, Cohen JL. Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 2001; 98: 3156-3158.
24. Godfrey WR, Krampf MR, Taylor PA, Blazar BR. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 2004; 103: 1158-1165.
25. Parr L. Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour. Br J Cancer 1972; 26: 174-177.
26. Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K et al. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol 1998; 161: 5268-5275.
27. Beck C, Schreiber K, Schreiber H, Rowley DA. C-kit + FcR + myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol 2003; 33: 19-28.
28. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 1995; 92: 6254-6258.
29. Hestdal K, Ruscetti FW, Ihle JN, Jacobsen SE, Dubois CM, Kopp WC et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 1991; 147: 22-28.
30. Storek J. B-cell immunity after allogeneic hematopoietic cell transplantation. Cytotherapy 2002; 4: 423-424.
31. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: Recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387-398.
32. Glass B, Uharek L, Zeis M, Dreger P, Loffler H, Steinmann J et al. Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect. Blood 1997; 90: 1694-1700.
33. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 2002; 100: 1894-1902.
34. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-877.
35. Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
36. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776.
37. Maury S, Mary JY, Rabian C, Schwarzinger M, Toubert A, Scieux C et al. Prolonged immune deficiency following allogeneic stem cell transplantation: Risk factors and complications in adult patients. Br J Haematol 2001; 115: 630-641.
38. Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96: 3290-3293.
39. Oettel KR, Wesly OH, Albertini MR, Hank JA, Iliopolis O, Sosman JA et al. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1 +) human leukemia lines can also recognize Ph1- cells from the same patient. Blood 1994; 83: 3390-3402.
40. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992; 175: 139-146.
41. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF et al. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17: 737-747.
42. Blazar BR, Lees CJ, Martin PJ, Noelle RJ, Kwon B, Murphy W et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol 2000; 165: 4901-4909.
43. Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
44. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2- specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747.